ClinicalTrials.gg
CompletedNCT05765357Updated Mar 13, 2023

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

A Phase 1 interventional study of Trastuzumab for injection and Herceptin in Metastatic Breast Cancer and Metastatic Gastric Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 7 months after the study started (first participant enrolled Jul 2017, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
140th of 366
89 · median 61
Started
2017
with 5 others
Phase 1
21 of 374
3 open now
Registered
329th of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 140th largest by enrollment of the 366 interventional ones that give a count, is one of 6 that started in 2017, is one of 21 in phase 1, and was the 329th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

Trastuzumab for injection is a biosimilar of Herceptin ® produced by Chia Tai Tianqing Biotechnology Co., LTD, which is a humanized IgG1 monoclonal antibody produced by chinese hamster ovary (CHO) cells. A randomized, double-blind, single-dose, parallel phase I study comparing trastuzumab for injection with Herceptin ® in healthy male volunteers was conducted to evaluate the similarities in pharmacokinetics, tolerability, safety and immunogenicity of Trastuzumab for injection and Herceptin®.

03

Conditions studied

  • Metastatic Breast Cancer
  • Metastatic Gastric Cancer
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand the purpose of the trial, and have a basic understanding of the pharmacological effects and possible adverse reactions of the drug under study; Voluntary written in accordance with the Helsinki Declaration;
  • Healthy male subjects aged ≥ 18 years and ≤ 65 years;
  • Body weight ≥ 50 kg ≤ 90 kg, ≥ 18 ≤ 28kg/m2;
  • The system examination indicators were within the normal range, or the examination results were abnormal but the researchers judged that there was no clinical significance;
  • Subjects agree to use reliable methods for both themselves and their partners during the study period and for 6 months after the study drug infusion.

Exclusion criteria

Exclusion Criteria:

  • History of hypertension or abnormal blood pressure at screening/baseline measurement;
  • A history of albuminuria or albuminuria as assessed by the investigator as ;
  • Received any antibody or protein targeting Vascular Endothelial Cell Growth Factor (VEGF) or VEGF receptors in the previous 1 year;
  • Study the use of any biological product or within 3 months prior to drug infusion, or the use of any monoclonal antibody within 12 months;
  • Have an inherited tendency to bleed or have coagulation dysfunction, or have a history of thrombosis or bleeding;
  • History of digestive tract perforation or digestive tract fistula;
  • Unhealed wound ulcers or fractures, or major surgery within 2 months prior to randomization or expected to be performed during the study period or within 2 months after study completion;
  • Use of a prescription or over-the-counter drug or nutritional supplement within the 5 half-life of the drug or nutritional supplement or within 2 weeks prior to the study drug use;
  • Positive virology test;
  • Known allergy to trastuzumab;
  • Known history of allergic diseases or allergic constitution;
  • Study the history of blood donation 3 months before drug infusion;
  • Received any other drug therapy or participated in another interventional clinical trial within 2 months prior to screening
  • A history of alcohol or drug abuse in the 12 months prior to screening;
  • A history of mental illness;
  • Subjects whose spouses plan to become pregnant;
  • The study cannot be completed according to protocol requirements during the study period;
  • Conditions considered unsuitable for inclusion by other researchers.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Trastuzumab for injection

    4mg/kg, Single dose for intravenous infusion

    Drug: Trastuzumab for injection

  • Active comparator
    Herceptin

    4mg/kg, Single dose for intravenous infusion

    Drug: Herceptin

Interventions

  • Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.

  • Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.

06

What researchers measure

Primary outcomes

  1. Area under drug concentration - time curve (AUC0-t)

    Area under the curve from time zero to the lowest detectable blood drug concentration

    Time frame: Within 30 minutes before administration to 1344 hours after administration

Secondary outcomes

  1. Area under drug concentration - time curve (AUC0-∞)

    The area under the curve extrapolating from time zero to infinity

    Time frame: Within 30 minutes before administration to 1344 hours after administration

  2. Peak concentration (Cmax)

    Peak maximum plasma drug concentration

    Time frame: Within 30 minutes before administration to 1344 hours after administration

  3. Time to reach maximum plasma (Tmax)

    Time to reach maximum plasma concentration after dosing

    Time frame: Within 30 minutes before administration to 1344 hours after administration

  4. Clearance (CL)

    Percentage of the body that eliminates organ-scavenging drugs

    Time frame: Within 30 minutes before administration to 1344 hours after administration

  5. half-life (T1/2)

    The time it takes for serum drug concentrations to drop by half

    Time frame: Within 30 minutes before administration to 1344 hours after administration

  6. Apparent volume of distribution (Vd/F)

    Apparent volume of distribution after administration

    Time frame: Within 30 minutes before administration to 1344 hours after administration

07

Study locations

1 site
  • Affiliated Hospital of Changchun University of Traditional Chinese Medicine
    Changchun, Jilin 130021, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Oct 2017, 3 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 3 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
Mar 13, 2023
StartActual
Jul 16, 2017
Primary completionActual
Oct 27, 2017
CompletionActual
Oct 27, 2017
Last update
Mar 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05765357
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
Jul 16, 2017
Primary completion
Oct 27, 2017
Completion
Oct 27, 2017
Last update
Mar 13, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion